Table 3. Assessment of grade 3/4 toxicities for entire cohort of patients who received gemcitabine and capecitabine (gem-cap).
| Toxicity | n (%) |
|---|---|
| Overall | 129 (100.0) |
| Any grade 3/4 toxicity | 69 (53.5) |
| Hematologic toxicity* | 46 (35.7) |
| Neutropenia | 34 (26.4) |
| Thrombocytopenia | 21 (16.3) |
| Anemia | 2 (1.6) |
| Infection | 33 (25.6) |
| Cholangitis | 16 (12.4) |
| Pneumonia | 6 (4.7) |
| Colitis | 4 (3.1) |
| Gastritis | 2 (1.6) |
| Cellulitis | 1 (0.8) |
| Sepsis | 4 (3.1) |
| Liver toxicity (elevated transaminases) | 12 (9.3) |
| Other toxicity* | 29 (22.3) |
| Fatigue | 12 (9.3) |
| Hand-foot syndrome | 9 (7.0) |
| Pneumonitis | 4 (3.1) |
| Edema | 3 (2.3) |
| Nausea | 2 (1.6) |
| Hemolytic-uremic syndrome | 1 (0.8) |
| COPD exacerbation | 1 (0.8) |
*, subtotals represent the number of patients with these toxicities. Patients may present with one or more of these toxicities such that the subtotal for these items is exceeded by the individual toxicities.